Patients with PMMRDIA have the worst outcome of all IDH mutant tumors with a median survival of 15 months which is comparable to IDH wild-type glioblastoma (Table 2) (Suwala et al., 2021). The gene discussed is IDH2; the disease is glioblastoma.